# HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

> **NCT05311319** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 70 (estimated)

## Conditions studied

- Hepatocarcinoma

## Interventions

- **DRUG:** HAIC+TQB2450+Anlotinib

## Key facts

- **NCT ID:** NCT05311319
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-11
- **Primary completion:** 2022-12
- **Final completion:** 2023-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05311319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05311319, "HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT05311319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*